Can a stronger flu shot better protect seniors?

NCT ID NCT07737106

Completed ⭐️ VACCINE ⭐️ Sponsor: Sinovac Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial is testing whether a high-dose flu vaccine is safe and triggers a stronger immune response in adults aged 60 and older compared to the standard-dose vaccine. Participants receive a single injection and are monitored for side effects and antibody levels. The goal is to see if a higher dose can offer better protection against influenza in this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a high-dose influenza vaccine (split virion, inactivated) containing 60 µg of hemagglutinin per strain
What this could lead to: If successful, this high-dose flu vaccine could offer better protection against influenza for older adults, who are at higher risk of severe illness.
What could go wrong: This is an early-phase trial with only 50 participants, so results may not apply to the general population. Higher doses can also increase the chance of side effects like injection-site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA

Contacts and locations

Locations

Urad Middle Banner Center for Disease Control and Prevention

Bayan Nur, Inner Mongolia, 015300, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.